r-16341
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2025 (NCT07206563)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetANTAGONIST
DRD2
Chemistry & pharmacology
Loading structure…
SMILES
OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1- Mol. weight
- 523.97 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL47050 ↗
Also known as
- penfluridol
- penfluridol
- penfluridol
- penfluridol
- penfluridol
- penfluridol
- r-16341
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07206563 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2025 | Huazhong University of Science and Technology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1